查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1658718

全球生物製药第三方物流(3PL) 市场依产品类型、供应链、服务类型、地区、趋势分析、竞争格局、预测（2019-2031 年）

Biopharmaceutical Third Party Logistics Market, By Product Type; By Supply Chain; By Service Type; By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2031
出版日期: | 出版商: Blueweave Consulting | 英文 550 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球生物製药第三方物流(3PL) 市场规模的主要推动因素是生物製药需求激增、低温运输物流蓬勃发展、全球医疗保健行业不断扩大、对法规合规性的重视以及技术进步的日益采用。

以金额为准，全球生物製药第三方物流(3PL) 市场规模估计到 2024 年将达到 1,306 亿美元。预计到 2031 年将达到 1,890 亿美元，在 2025-2031 年预测期内以 5.6% 的健康复合年增长率成长。推动市场发展的因素包括对温度敏感生技药品的需求不断增长、生物製药供应链日益全球化以及为提高效率和成本效益而不断上升的外包趋势。药品安全和品质的严格监管要求、低温运输物流技术的进步以及不断扩张的生物製药行业进一步推动了市场的成长。此外，对生技药品、疫苗和特殊药物的需求激增以及对专业化处理和分销的需求正在推动全球生物製药第三方物流服务市场的成长。

机会－数位科技的日益普及

全球生物製药第三方物流(3PL) 市场由数位技术的日益采用所推动，这些技术提高了供应链的效率和透明度。物联网、人工智慧、区块链和资料分析等先进解决方案优化了即时追踪、温度监控和库存管理，以确保敏感生物製药产品的完整性。先进的技术有助于提高业务效率、降低风险并支援法规遵循性，满足生物製药产业对安全高效物流解决方案日益增长的需求。

生技药品产品类型细分市场主导全球生物製药第三方物流市场

生技药品是全球生物製药第三方物流（3PL）市场的主要产品类型。生技药品在市场上占据主导地位，是由于对温度敏感的生技药品的需求不断增加，这些生物製剂需要专门的储存和运输解决方案。复杂的处理要求、严格的法规遵循以及越来越多的慢性病生物疗法促进了这一领域的扩张。此外，低温运输物流的进步和新兴市场对生技药品的日益采用，进一步提升了该领域在全球第三方物流领域的地位。

地缘政治紧张局势加剧对全球生物製药第三方物流(3PL) 市场的影响

全球生物製药第三方物流(3PL) 市场透过提高生物製药分销的效率、可靠性和成本效益，对医疗保健供应链产生了重大影响。我们也支持温度敏感产品的处理，透过先进的低温运输物流确保生技药品、疫苗和特殊药品的完整性。 3PL 供应商提供仓储、库存管理、法规合规和即时追踪等专业服务，以简化製药公司的业务。这使得生物製药公司能够更快进入市场、降低营运成本并专注于研发等核心业务。此外，全球对生技药品、个人化医疗和医疗保健的需求不断增长，正在推动市场扩张。第三方物流产业也透过采用数位技术、自动化和资料分析来推动创新，以在日益复杂的全球环境中提高供应链的可视性和弹性。

竞争格局

全球生物製药第三方物流（3PL）市场高度分散，有大量公司参与市场。主导市场的主要企业有：DHL International GmbH、顺丰速递、美国联合包裹服务公司 (UPS)、AmerisourceBergen Corp、DB Schenker、Kuehne and Nagel、嘉里物流网络有限公司、Agility 等。公司采用的关键行销策略是设施扩建、产品多样化、联盟、合作、伙伴关係、收购等，以扩大客户范围并在全球生物製药第三方物流(3PL) 市场的竞争中获得竞争优势。

本报告对全球生物製药第三方物流（3PL）市场进行了深入分析，并提供了有关成长潜力和未来趋势的资讯。它还分析了市场的成长动力、挑战和竞争动态。

目录

第一章 调查框架

第 2 章执行摘要

第 3 章全球生物製药第三者物流(3PL)市场考察考量

  • 产业价值链分析
  • DROC 分析
    • 成长动力
      • 技术进步
      • 对温度敏感产品的需求不断增加
      • 医疗全球化
    • 限制因素
      • 严格遵守法规
      • 初期投资高
    • 机会
      • 采用数位技术
      • 外包趋势
    • 任务
      • 操作风险
      • 市场竞争
  • 科技进步/最新发展
  • 法规结构
  • 波特五力分析

第 4 章：全球生物製药第三方物流(3PL) 行销策略

第 5 章全球生物製药第三方物流(3PL) 市场：定价分析

第六章全球生物製药第三方物流(3PL) 市场概述

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 依产品类型
      • 疫苗
      • 生技药品
      • 血浆疗法
    • 按供应链
      • 低温运输物流
      • 非低温运输物流
    • 按服务类型
      • 运输
      • 仓储和储存
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

7. 北美生物製药第三方物流(3PL) 市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 依产品类型
    • 按供应链
    • 按服务类型
    • 按国家
      • 美国
      • 加拿大

8. 欧洲生物製药第三方物流(3PL) 市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 依产品类型
    • 按供应链
    • 按服务类型
    • 按国家
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 欧洲其他地区

9. 亚太生物製药第三人物流(3PL) 市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 依产品类型
    • 按供应链
    • 按服务类型
    • 按国家
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

10. 拉丁美洲生物製药第三方物流(3PL) 市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 依产品类型
    • 按供应链
    • 按服务类型
    • 按国家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲国家

第 11 章中东和非洲生物製药第三方物流(3PL) 市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 依产品类型
    • 按供应链
    • 按服务类型
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东和非洲地区

第十二章 竞争格局

  • 主要企业及其产品列表
  • 全球生物製药第三方物流(3PL) 市场公司市场占有率分析（2024 年）
  • 竞争性基准化分析：根据业务参数
  • 重大策略发展（合併、收购、联盟）

第 13 章地缘政治紧张局势加剧对全球生物製药第三方物流(3PL) 市场的影响

第 14 章 公司简介（公司概况、财务矩阵、竞争格局、关键人员、主要竞争对手、联繫、策略展望、SWOT 分析）

  • DHL International GmbH
  • SF Express
  • United Parcel Service of America Inc. (UPS)
  • AmerisourceBergen Corp.
  • DB Schenker
  • Kuehne and Nagel
  • Kerry Logistics Network Ltd
  • Agility
  • 其他知名公司

第 15 章 关键策略建议

第十六章调查方法

简介目录
Product Code: BWC25078

Global Biopharmaceutical Third Party Logistics (3PL) Market to Reach USD 189 Billion by 2031

Global Biopharmaceutical Third Party Logistics (3PL) Market is booming primarily due to a surging demand for biopharmaceuticals, thriving cold chain logistics, expanding global healthcare sector, an increasing focus on complying with regulations, and the growing adoption of technological advancements.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Biopharmaceutical Third Party Logistics (3PL) Market size by value at USD 130.6 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Biopharmaceutical Third Party Logistics (3PL) Market size to boom at a robust CAGR of 5.6% reaching a value of USD 189 billion by 2031. The Global Market for Biopharmaceutical Third Party Logistics (3PL) is driven by the rising demand for temperature-sensitive biologics, increasing globalization of biopharmaceutical supply chains, and growing outsourcing trends to enhance efficiency and cost-effectiveness. Stringent regulatory requirements for drug safety and quality, advancements in cold chain logistics technologies, and the expansion of the biopharmaceutical industry further propel market growth. Additionally, the surging demand for biologics, vaccines, and specialty drugs, along with the need for specialized handling and distribution, boosts the growth of Global Biopharmaceutical 3PL Services Market.

Opportunity - Growing Adoption of Digital Technologies

Global Biopharmaceutical Third Party Logistics (3PL) Market is driven by the growing adoption of digital technologies, enhancing supply chain efficiency and transparency. Advanced solutions like IoT, AI, blockchain, and data analytics optimize real-time tracking, temperature monitoring, and inventory management, ensuring the integrity of sensitive biopharmaceutical products. Advanced technologies help in improving operational efficiency, reducing risks, and supporting regulatory compliance, meeting the growing demand for secure and efficient logistics solutions in the biopharmaceutical industry.

Biologics Product Type Segment Dominates Global Biopharma 3PL Market

The biologics segment is the leading product type in Global Biopharmaceutical Third Party Logistics (3PL) Market. Biologics' market dominance is driven by an increasing demand for temperature-sensitive biologic drugs, requiring specialized storage and transportation solutions. The complex handling requirements, strict regulatory compliance, and growth in biologic therapies for chronic diseases contribute to the segment's expansion. Additionally, advancements in cold chain logistics and the rising adoption of biologics in emerging markets further boost this segment's prominence in the global 3PL landscape.

Impact of Escalating Geopolitical Tensions on Global Biopharmaceutical Third Party Logistics (3PL) Market

Global Biopharmaceutical Third-Party Logistics (3PL) Market significantly impacts the healthcare supply chain by enhancing the efficiency, reliability, and cost-effectiveness of biopharmaceutical distribution. It supports temperature-sensitive product handling, ensuring the integrity of biologics, vaccines, and specialty drugs through advanced cold chain logistics. 3PL providers offer specialized services like warehousing, inventory management, regulatory compliance, and real-time tracking, which streamline operations for pharmaceutical companies. It enables faster market access, reduces operational costs, and allows biopharma firms to focus on core activities like R&D. Additionally, the growing demand for biologics, personalized medicine, and global healthcare access has driven the market's expansion. The 3PL sector also fosters innovation through the adoption of digital technologies, automation, and data analytics, enhancing supply chain visibility and resilience in an increasingly complex global environment.

Competitive Landscape

Global Biopharmaceutical Third Party Logistics (3PL) Market is highly fragmented, with numerous players serving the market. Major companies dominating the market include DHL International GmbH, SF Express, United Parcel Service of America Inc. (UPS), AmerisourceBergen Corp, DB Schenker, Kuehne and Nagel, Kerry Logistics Network Ltd, and Agility. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in Global Biopharmaceutical Third Party Logistics (3PL) Market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and Global Biopharmaceutical Third Party Logistics (3PL) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Biopharmaceutical Third Party Logistics (3PL) Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Biopharmaceutical Third Party Logistics (3PL)Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Technological Advancements
      • 3.2.1.2. Increasing Demand for Temperature-Sensitive Products
      • 3.2.1.3. Globalization of Healthcare
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent Regulatory Compliance
      • 3.2.2.2. High Initial Investment
    • 3.2.3. Opportunities
      • 3.2.3.1. Adoption of Digital Technologies
      • 3.2.3.2. Outsourcing Trends
    • 3.2.4. Challenges
      • 3.2.4.1. Operational Risks
      • 3.2.4.2. Market Competition
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Biopharmaceutical Third Party Logistics (3PL)Marketing Strategies

5. Global Biopharmaceutical Third Party Logistics (3PL)Market: Pricing Analysis

6. Global Biopharmaceutical Third Party Logistics (3PL)Market Overview

  • 6.1. Market Size & Forecast, 2019-2031
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
      • 6.2.1.1. Vaccines
      • 6.2.1.2. Biologics
      • 6.2.1.3. Blood Plasma-based Therapies
    • 6.2.2. By Supply Chain
      • 6.2.2.1. Cold Chain Logistics
      • 6.2.2.2. Non-Cold Chain Logistics
    • 6.2.3. By Service Type
      • 6.2.3.1. Transportation
      • 6.2.3.2. Warehousing & Storage
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America Biopharmaceutical Third Party Logistics (3PL) Market

  • 7.1. Market Size & Forecast, 2019-2031
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Supply Chain
    • 7.2.3. By Service Type
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Product Type
      • 7.2.4.1.2. By Supply Chain
      • 7.2.4.1.3. By Service Type
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Product Type
      • 7.2.4.2.2. By Supply Chain
      • 7.2.4.2.3. By Service Type

8. Europe Biopharmaceutical Third Party Logistics (3PL) Market

  • 8.1. Market Size & Forecast, 2019-2031
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Supply Chain
    • 8.2.3. By Service Type
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Product Type
      • 8.2.4.1.2. By Supply Chain
      • 8.2.4.1.3. By Service Type
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Product Type
      • 8.2.4.2.2. By Supply Chain
      • 8.2.4.2.3. By Service Type
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Product Type
      • 8.2.4.3.2. By Supply Chain
      • 8.2.4.3.3. By Service Type
      • 8.2.4.4. France
      • 8.2.4.4.1. By Product Type
      • 8.2.4.4.2. By Supply Chain
      • 8.2.4.4.3. By Service Type
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Product Type
      • 8.2.4.5.2. By Supply Chain
      • 8.2.4.5.3. By Service Type
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Product Type
      • 8.2.4.6.2. By Supply Chain
      • 8.2.4.6.3. By Service Type
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Product Type
      • 8.2.4.7.2. By Supply Chain
      • 8.2.4.7.3. By Service Type
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Product Type
      • 8.2.4.8.2. By Supply Chain
      • 8.2.4.8.3. By Service Type
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Product Type
      • 8.2.4.9.2. By Supply Chain
      • 8.2.4.9.3. By Service Type

9. Asia Pacific Biopharmaceutical Third Party Logistics (3PL) Market

  • 9.1. Market Size & Forecast, 2019-2031
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Supply Chain
    • 9.2.3. By Service Type
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Product Type
      • 9.2.4.1.2. By Supply Chain
      • 9.2.4.1.3. By Service Type
      • 9.2.4.2. India
      • 9.2.4.2.1. By Product Type
      • 9.2.4.2.2. By Supply Chain
      • 9.2.4.2.3. By Service Type
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Product Type
      • 9.2.4.3.2. By Supply Chain
      • 9.2.4.3.3. By Service Type
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Product Type
      • 9.2.4.4.2. By Supply Chain
      • 9.2.4.4.3. By Service Type
      • 9.2.4.5. Australia and New Zealand
      • 9.2.4.5.1. By Product Type
      • 9.2.4.5.2. By Supply Chain
      • 9.2.4.5.3. By Service Type
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Product Type
      • 9.2.4.6.2. By Supply Chain
      • 9.2.4.6.3. By Service Type
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Product Type
      • 9.2.4.7.2. By Supply Chain
      • 9.2.4.7.3. By Service Type
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Product Type
      • 9.2.4.8.2. By Supply Chain
      • 9.2.4.8.3. By Service Type
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Product Type
      • 9.2.4.9.2. By Supply Chain
      • 9.2.4.9.3. By Service Type
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Product Type
      • 9.2.4.10.2. By Supply Chain
      • 9.2.4.10.3. By Service Type

10. Latin America Biopharmaceutical Third Party Logistics (3PL) Market

  • 10.1. Market Size & Forecast, 2019-2031
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Supply Chain
    • 10.2.3. By Service Type
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Product Type
      • 10.2.4.1.2. By Supply Chain
      • 10.2.4.1.3. By Service Type
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Product Type
      • 10.2.4.2.2. By Supply Chain
      • 10.2.4.2.3. By Service Type
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Product Type
      • 10.2.4.3.2. By Supply Chain
      • 10.2.4.3.3. By Service Type
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Product Type
      • 10.2.4.4.2. By Supply Chain
      • 10.2.4.4.3. By Service Type
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Product Type
      • 10.2.4.5.2. By Supply Chain
      • 10.2.4.5.3. By Service Type

11. Middle East and Africa Biopharmaceutical Third Party Logistics (3PL) Market

  • 11.1. Market Size & Forecast, 2019-2031
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Type
    • 11.2.2. By Supply Chain
    • 11.2.3. By Service Type
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Product Type
      • 11.2.4.1.2. By Supply Chain
      • 11.2.4.1.3. By Service Type
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Product Type
      • 11.2.4.2.2. By Supply Chain
      • 11.2.4.2.3. By Service Type
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Product Type
      • 11.2.4.3.2. By Supply Chain
      • 11.2.4.3.3. By Service Type
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Product Type
      • 11.2.4.4.2. By Supply Chain
      • 11.2.4.4.3. By Service Type
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Product Type
      • 11.2.4.5.2. By Supply Chain
      • 11.2.4.5.3. By Service Type
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Product Type
      • 11.2.4.6.2. By Supply Chain
      • 11.2.4.6.3. By Service Type
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Product Type
      • 11.2.4.7.2. By Supply Chain
      • 11.2.4.7.3. By Service Type
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Product Type
      • 11.2.4.8.2. By Supply Chain
      • 11.2.4.8.3. By Service Type

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global Biopharmaceutical Third Party Logistics (3PL) Market Company Market Share Analysis, 2024
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

13. Impact of Escalating Geopolitical Tensions on Global Biopharmaceutical Third Party Logistics (3PL) Market

14. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 14.1. DHL International GmbH
  • 14.2. SF Express
  • 14.3. United Parcel Service of America Inc. (UPS)
  • 14.4. AmerisourceBergen Corp.
  • 14.5. DB Schenker
  • 14.6. Kuehne and Nagel
  • 14.7. Kerry Logistics Network Ltd
  • 14.8. Agility
  • 14.9. Other Prominent Players

15. Key Strategic Recommendations

16. Research Methodology

  • 16.1. Qualitative Research
    • 16.1.1. Primary & Secondary Research
  • 16.2. Quantitative Research
  • 16.3. Market Breakdown & Data Triangulation
    • 16.3.1. Secondary Research
    • 16.3.2. Primary Research
  • 16.4. Breakdown of Primary Research Respondents, By Region
  • 16.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable